Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

TTRX

Turn Therapeutics Inc

Jun 01 • 02:36PM ET

6.68

+1.48 28.48 %

Healthcare • Biotechnology • USA • Micro • NASD

Today, 9:05 AMTurn Therapeutics reports positive interim Phase 2 GX-03 data in moderate-to-severe atopic dermatitis with strong early efficacy and favorable safety

Peers: AARD AGEN CNTB GALT GUTS IMUX KZIA NTHI SPRO VRCA

| Held by: VTI

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.18	Insider Own	63.78%	Shs Outstand	29.79M	Perf Week	30.23%
Market Cap	199.01M	Forward P/E	-	EPS next Y	-	Insider Trans	0.01%	Shs Float	10.79M	Perf Month	81.04%
Enterprise Value	193.80M	PEG	-	EPS next Q	-	Inst Own	1.73%	Short Float	0.60%	Perf Quarter	82.54%
Income	-3.84M	P/S	-	EPS this Y	-	Inst Trans	-2.02%	Short Ratio	2.15	Perf Half Y	96.49%
Sales	0.00M	P/B	32.53	EPS next Y	-	ROA	-	Short Interest	0.06M	Perf YTD	69.56%
Book/sh	0.21	P/C	17.74	EPS next 5Y	-	ROE	-	52W High	26.50 -74.79%	Perf Year	-
Cash/sh	0.38	P/FCF	-	EPS past 3/5Y	29.26% -	ROIC	-31.77%	52W Low	2.57 159.94%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.73% 8.44%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-37.24%	Oper. Margin	-	ATR (14)	0.46	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.23	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	85.21	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.23	EPS Q/Q	-193.75%	SMA20	47.02%	Beta	-	Target Price	8.00
Payout	-	Debt/Eq	0.98	Sales Q/Q	-	SMA50	72.48%	Rel Volume	8.81	Prev Close	5.20
Employees	2	LT Debt/Eq	0.97	Earnings	May 11 AMC	SMA200	66.38%	Avg Volume	30.01K	Price	6.68
IPO	Oct 08, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	-50.00% -	Trades		Volume	210,175	Change	28.48%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-29-25	Initiated	D. Boral Capital	Buy	$8

Today 08:30AM	Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis (Business Wire) +28.48%
May-27-26 08:05AM	Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model (Business Wire)
May-19-26 08:01AM	Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026 (Business Wire) -7.14%
May-18-26 08:05AM	Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead (Business Wire) +20.99%
May-11-26 04:05PM	Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates (Business Wire)
04:05PM	Loading…
Mar-31-26 04:05PM	Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates (Business Wire)
Mar-24-26 08:00AM	Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group (Business Wire)
Mar-02-26 01:08AM	Turn Therapeutics Talks GX-03 Phase II Eczema Data Timeline and Non-Systemic Topical Strategy (MarketBeat)
Feb-17-26 08:00AM	Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs (Business Wire) -8.83%
Feb-09-26 08:00AM	Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences (Business Wire)
Jan-12-26 08:05AM	Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference (Business Wire) -8.44%
Jan-07-26 04:05PM	Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors (GlobeNewswire)
Dec-29-25 07:52AM	Here Are Mondays Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More (24/7 Wall St.) +14.60%
Nov-13-25 08:00AM	Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) -7.05%
Nov-11-25 04:05PM	Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D. (GlobeNewswire) -6.05% +13.40%
08:00AM	Loading…
08:00AM	Turn Therapeutics' GX-03 Technology Named as One of "Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment" by Patient Care Online Magazine (GlobeNewswire)
Nov-04-25 05:07PM	Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications (GlobeNewswire)
Oct-30-25 07:30AM	Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline (GlobeNewswire)
Oct-22-25 08:00AM	Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones (GlobeNewswire) -11.81%
Oct-20-25 08:22AM	Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025 (GlobeNewswire)
Oct-15-25 08:00AM	Turn Therapeutics Appoints Dr. Kent Kester to Board of Directors (GlobeNewswire) -14.57%
Oct-14-25 12:07PM	Turn Therapeutics Appoints Arthur Golden to Board of Directors (GlobeNewswire) -8.29%
Oct-08-25 08:00AM	Turn Therapeutics to Commence Trading Today on Nasdaq (GlobeNewswire)

Turn Therapeutics, Inc. is a pharmaceutical and medical device development company. Its primary development programs focus on dermatological diseases. The company was founded by Bradley Burnam on January 6, 2015 and is headquartered in Westlake Village, CA.

FounderMr. Bradley E. Burnam

Interim CFOMr. Zuraiz Chaudhary

Chief Medical Officer & DirectorDr. Neilesh Shailesh Ghodadra M.D.

ControllerMohammed Zubair

M.D.Dr. Stephen M. Hahn FASTRO

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chaudhary Zuraiz	See Remarks	Dec 12 '25	Buy	3.50	2,500	8,750	12,500	Dec 12 06:00 PM
GOLDEN ARTHUR F	Director	Nov 24 '25	Buy	3.44	9,868	33,946	60,602	Nov 25 09:00 PM
GOLDEN ARTHUR F	Director	Nov 21 '25	Buy	2.87	20,532	58,927	50,734	Nov 24 07:13 AM
Chaudhary Zuraiz	See Remarks	Nov 20 '25	Buy	2.61	1,450	3,784	9,000	Nov 21 05:43 PM
Chaudhary Zuraiz	See Remarks	Nov 21 '25	Buy	3.29	1,000	3,290	10,000	Nov 21 05:43 PM
Chaudhary Zuraiz	See Remarks	Nov 17 '25	Buy	3.62	2,500	9,050	7,550	Nov 17 09:23 PM
Chesed Abraham	Board Observer	Oct 23 '25	Buy	4.60	14,286	65,716	1,447,268	Oct 29 08:43 PM
Chaudhary Zuraiz	See Remarks	Oct 23 '25	Buy	4.95	5,050	24,998	5,050	Oct 23 09:03 PM
GOLDEN ARTHUR F	Director	Oct 23 '25	Buy	4.95	20,202	100,000	30,202	Oct 23 09:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TTRX

Turn Therapeutics Inc

Upgrade your Finviz experience